SOURCE: CDEX Inc.

January 17, 2008 09:30 ET

CDEX Inc. Announces Expansion of Its ValiMed™ Marketing & Sales Team in the UK

Mr. David Smuts Joins CDEX Inc. to Spearhead Marketing and Sales of ValiMed™ in the UK

TUCSON, AZ and PARIS and LONDON--(Marketwire - January 17, 2008) - CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international business development by announcing today that Mr. David Smuts has joined CDEX to drive the marketing and sales of ValiMed in the United Kingdom and Ireland. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

Mr. Smuts is a seasoned and knowledgeable business manager experienced in working with senior level executives in the government and the public/private sectors of the healthcare industry. He has a proven track record of initiating and developing new technology solutions for the international healthcare market. Most recently, Mr. Smuts was the Business Manager for Cardinal Health Inc.'s Pyxis pharmacy automation solution for the UK and Ireland, where he developed reference test sites, drove quick adoption of the new-to market technologies and secured record contracts with the Nation Health Service. Currently Mr. Smuts chairs the Health Study Group of the UK Labour Finance and Industry Group (LFIG), which provides policy advice to government ministers including those from the department of health.

"Prevention of medication errors and improving patient safety are top priorities within all hospitals in the UK and in particular at all levels in the National Health Service," said Mr. Smuts. "ValiMed provides a unique solution to help pharmacists and care givers work towards this goal."

"We are very pleased to have someone of David's caliber and experience to lead our sales and marketing efforts in the UK and in Ireland," said Pascal Pouligny, CDEX Vice President of International Sales & Marketing. "This is a very important step in our international development plan and we are very committed to providing our UK customers with excellent sales and service support from day one. We also hope to announce further appointments in the near future."

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny (ppoulignyt@cdex-inc.com) at 520.745.5172 X 210 or 202.

ANY STATEMENTS MADE IN THIS PRESS RELEASE WHICH CONTAIN INFORMATION THAT IS NOT HISTORICAL ARE ESSENTIALLY FORWARD-LOOKING, AS THAT TERM IS DEFINED IN THE FEDERAL SECURITIES LAWS. MANY FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF WORDS SUCH AS "EXPECTS," "PLANS," "MAY," "ANTICIPATES," "BELIEVES," "SHOULD," "INTENDS," "ESTIMATES," AND OTHER WORDS OF SIMILAR MEANING. THESE STATEMENTS ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT CANNOT BE PREDICTED OR QUANTIFIED AND, CONSEQUENTLY, ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. SUCH RISKS AND UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE ABILITY OF THE COMPANY TO RAISE CAPITAL TO FINANCE THE DEVELOPMENT OF ITS PRODUCTS, THE EFFECTIVENESS, PROFITABILITY AND MARKETABILITY OF THOSE PRODUCTS, THE ABILITY OF THE COMPANY TO PROTECT ITS PROPRIETARY INFORMATION, THE ESTABLISHMENT OF AN EFFICIENT CORPORATE OPERATING STRUCTURE AS THE COMPANY GROWS AND, OTHER RISKS DETAILED FROM TIME-TO-TIME IN FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. THERE IS NO OBLIGATION TO PUBLICLY UPDATE ANY FORWARD-LOOKING STATEMENTS.

Contact Information